DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
作者信息
Dicker Dror
机构信息
Internal Medicine D and Obesity Clinic, Hasharon Hospital, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
出版信息
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S276-8. doi: 10.2337/dc11-s229.
Abstract
摘要
相似文献
1
DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S276-8. doi: 10.2337/dc11-s229.
2
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med. 2014 Jul 24;156(13):74-5.
3
DPP-4 inhibitors in clinical practice.
Postgrad Med. 2009 Nov;121(6):70-100. doi: 10.3810/pgm.2009.11.2079.
4
[Use of vildagliptin from an internal disease specialists point of view].
Vnitr Lek. 2013 Apr;59(4):322-4.
5
[Vildagliptin].
Nihon Rinsho. 2011 May;69(5):865-70.
6
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Nihon Yakurigaku Zasshi. 2010 Nov;136(5):299-308. doi: 10.1254/fpj.136.299.
7
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int. 2013 May;22(138):121.
8
Vildagliptin in clinical practice: a review of literature.
Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 10.1517/14656560903302265.
9
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):403-413. doi: 10.1016/j.bbagen.2017.11.012. Epub 2017 Dec 22.
10
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Curr Top Med Chem. 2008;8(17):1545-52. doi: 10.2174/156802608786413519.
引用本文的文献
1
Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets.
J Comput Aided Mol Des. 2025 Aug 13;39(1):66. doi: 10.1007/s10822-025-00646-9.
2
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome.
Pharmaceutics. 2025 Jun 11;17(6):768. doi: 10.3390/pharmaceutics17060768.
3
Effects of Sulfonylureas and Dipeptidyl Peptidase 4 Inhibitors on Percentage Body Fat Change in Type 2 Diabetes Mellitus Patients on Metformin at 4 and 12 Weeks.
Cureus. 2024 Sep 26;16(9):e70255. doi: 10.7759/cureus.70255. eCollection 2024 Sep.
4
Role of Metalloproteinases in Diabetes-associated Mild Cognitive Impairment.
Curr Neuropharmacol. 2024;23(1):58-74. doi: 10.2174/1570159X22666240517090855.
5
Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.
Front Endocrinol (Lausanne). 2024 May 31;15:1403606. doi: 10.3389/fendo.2024.1403606. eCollection 2024.
6
Angioedema From Triple Therapy: A Case Report.
Cureus. 2023 Sep 30;15(9):e46247. doi: 10.7759/cureus.46247. eCollection 2023 Sep.
7
Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Am J Physiol Cell Physiol. 2023 Oct 1;325(4):C972-C980. doi: 10.1152/ajpcell.00246.2023. Epub 2023 Aug 29.
8
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.
Front Mol Biosci. 2023 May 23;10:1130625. doi: 10.3389/fmolb.2023.1130625. eCollection 2023.
9
Exploitation of Olive ( L.) Seed Proteins as Upgraded Source of Bioactive Peptides with Multifunctional Properties: Focus on Antioxidant and Dipeptidyl-Dipeptidase-IV Inhibitory Activities, and Glucagon-like Peptide 1 Improved Modulation.
Antioxidants (Basel). 2022 Aug 31;11(9):1730. doi: 10.3390/antiox11091730.
10
Heterocyclic compounds as a magic bullet for diabetes mellitus: a review.
RSC Adv. 2022 Aug 16;12(35):22951-22973. doi: 10.1039/d2ra02697j. eCollection 2022 Aug 10.
本文引用的文献
1
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Hypertension. 2010 Oct;56(4):728-33. doi: 10.1161/HYPERTENSIONAHA.110.156554. Epub 2010 Aug 2.
2
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Postgrad Med. 2010 May;122(3):16-27. doi: 10.3810/pgm.2010.05.2138.
3
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.
4
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1454-65. doi: 10.1152/ajpheart.00867.2009. Epub 2010 Mar 5.
5
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Diabetes. 2010 Apr;59(4):1063-73. doi: 10.2337/db09-0955. Epub 2010 Jan 22.
6
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Circ Cardiovasc Imaging. 2010 Mar;3(2):195-201. doi: 10.1161/CIRCIMAGING.109.899377. Epub 2010 Jan 14.
7
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.
Diabetologia. 2010 Mar;53(3):552-61. doi: 10.1007/s00125-009-1611-5. Epub 2009 Dec 3.
8
Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.
Cleve Clin J Med. 2009 Dec;76 Suppl 5:S28-38. doi: 10.3949/ccjm.76.s5.05.
9
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
J Clin Endocrinol Metab. 2009 Mar;94(3):846-52. doi: 10.1210/jc.2008-1400. Epub 2008 Dec 16.
10
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
BMC Endocr Disord. 2008 Oct 27;8:14. doi: 10.1186/1472-6823-8-14.
Zotero 插件